Guardant Health (GH) to Appeal Federal District Court Verdict
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Guardant Health to Appeal Federal District Court Verdict
November 15, 2023 3:00 AM ESTPALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterdays verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington.
We strongly disagree with this decision and will vigorously appeal for its overturn, said Helmy Eltoukhy, Guardant Health co-founder and co-CEO. We believe the ruling ignores the strengths and merits of our R&D and intellectual property, which we painstakingly developed for... More
